ArticleNeoplasia (New York, N.Y.)2014

E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.

Armin Wiegering et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.